Repligen (RGEN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 27. Analyst Puneet Souda from Leerink Partners maintained a Buy rating on the stock and has a $200.00 price target.
Puneet Souda has given his Buy rating due to a combination of factors that suggest a promising outlook for Repligen. The company is experiencing strong order momentum, particularly in the fourth quarter, which sets the stage for mid-single to high-single-digit growth in the coming years. This growth is supported by Repligen’s diverse product portfolio and expanding infrastructure, which positions the company well for future opportunities.
Additionally, Repligen’s minimal exposure to NIH funding insulates it from some of the financial pressures affecting smaller biotech firms. The company is also strategically positioned to benefit from the accelerating innovation in China, particularly in the bispecifics market, while maintaining a competitive edge in the U.S. and EU. Furthermore, Repligen’s ability to manage tariff risks and capitalize on U.S. biomanufacturing investments, along with its focus on mergers and acquisitions to enhance scale and platform depth, further supports the Buy rating.
RGEN’s price has also changed slightly for the past six months – from $145.930 to $137.120, which is a -6.04% drop .